Jean‐Marc Tréluyer

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Jérôme Hadjadj, Nader Yatim, Laura Barnabei et al. · Science · 2020 · 3.1K citations · Full text

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Pierre Quartier, Florence Allantaz, Rolando Cimaz et al. · Annals of the Rheumatic Diseases · 2010 · 543 citations · Full text

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Daouda Sissoko, Cédric Laouenan, Elin Folkesson et al. · PLoS Medicine · 2016 · 477 citations · Full text

Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome

Salima Hacein-Bey Abina, H. Bobby Gaspar, Johanna Blondeau et al. · JAMA · 2015 · 374 citations · Full text

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients

Jérôme Hadjadj, Nader Yatim, Laura Barnabei et al. · 2020 · 253 citations · Full text

Immunodeficiencies, Immunology, Severe Covid-19 Patients +19